Patents by Inventor Daisuke Shii

Daisuke Shii has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230190716
    Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.
    Type: Application
    Filed: February 16, 2023
    Publication date: June 22, 2023
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki Miyake, Tomoko ODA, Daisuke SHII
  • Patent number: 11612590
    Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: March 28, 2023
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki Miyake, Tomoko Oda, Daisuke Shii
  • Publication number: 20190359577
    Abstract: The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.
    Type: Application
    Filed: August 6, 2019
    Publication date: November 28, 2019
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Kenji KAWASHIMA, Yusuke YAMAZAKI, Shinji TAKAOKA, Daisuke SHII, Tomoko ODA, Takahiro MATSUYAMA
  • Patent number: 10435379
    Abstract: The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: October 8, 2019
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji Kawashima, Yusuke Yamazaki, Shinji Takaoka, Daisuke Shii, Tomoko Oda, Takahiro Matsuyama
  • Publication number: 20190255026
    Abstract: A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.
    Type: Application
    Filed: May 7, 2019
    Publication date: August 22, 2019
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki MIYAKE, Tomoko ODA, Daisuke SHII
  • Publication number: 20190106393
    Abstract: The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.
    Type: Application
    Filed: December 5, 2018
    Publication date: April 11, 2019
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji KAWASHIMA, Yusuke YAMAZAKI, Shinji TAKAOKA, Daisuke SHII, Tomoko ODA, Takahiro MATSUYAMA
  • Patent number: 10189796
    Abstract: The present invention relates to a novel [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or a salt thereof. The compound or a salt thereof of the present invention has a glucocorticoid receptor agonist activity, and is useful as a medicine, in particular as a prophylactic or therapeutic agent for the glucocorticoid receptor related disease.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: January 29, 2019
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji Kawashima, Yusuke Yamazaki, Shinji Takaoka, Daisuke Shii, Tomoko Oda, Takahiro Matsuyama
  • Publication number: 20180244633
    Abstract: The present invention relates to a novel [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or a salt thereof. The compound or a salt thereof of the present invention has a glucocorticoid receptor agonist activity, and is useful as a medicine, in particular as a prophylactic or therapeutic agent for the glucocorticoid receptor related disease.
    Type: Application
    Filed: August 25, 2016
    Publication date: August 30, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji KAWASHIMA, Yusuke YAMAZAKI, Shinji TAKAOKA, Daisuke SHII, Tomoko ODA, Takahiro MATSUYAMA
  • Publication number: 20180021314
    Abstract: A method for treatment of meibomian gland dysfunction in a mammalian subject, the method involving administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to the eyes of the mammalian subject 1 to 2 times per day.
    Type: Application
    Filed: October 2, 2017
    Publication date: January 25, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki MIYAKE, Tomoko ODA, Daisuke SHII
  • Publication number: 20160022648
    Abstract: A compound represented by the formula (1): wherein R1 represents a hydroxyl group, a dimethylphosphynoyloxy group, etc.; and R2 and R3 represent a methoxy group, etc., or a pharmaceutically acceptable salt thereof can reduce a score of telangiectasia around the meibomian gland orifices and a number of obstruction at the orifices, so that it is useful as a prophylactic and/or therapeutic agent for meibomian gland dysfunction.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki MIYAKE, Tomoko ODA, Daisuke SHII
  • Publication number: 20140121901
    Abstract: A power source control system, a power source controller, and a power source control method capable of switching between supply and shut-off of power for electronic devices, individually for a plurality of electronic devices connected to a network, are provided. If a power source controller shuts off a power source for the Electronic Control Unit (ECU) by outputting a control signal to a power source switch device, the power source controller cyclically transmits data in place of the ECU. The other ECU for which a power source is not shut off can receive data equivalent to the data to be cyclically transmitted by the ECU for which the power source is shut off, from the power source controller. The power source controller stores a transmission cycle, a transmission ID, and latest reception information of each control target ECU, and performs substitute transmission of data.
    Type: Application
    Filed: April 25, 2012
    Publication date: May 1, 2014
    Applicants: AUTONETWORKS TECHNOLOGIES, LTD., SUMITOMO ELECTRIC INDUSTRIES, LTD., SUMITOMO WIRING SYSTEMS, LTD.
    Inventor: Daisuke Shii
  • Publication number: 20080119498
    Abstract: An object of the present invention is to find a novel pharmacological effect (a medicinal use) of a p38 MAP kinase inhibitor. Because of having an excellent antipruritic effect, a p38 MAP kinase inhibitor is useful as a therapeutic agent for pruritus of any types such as ocular pruritus, skin pruritus and systemic pruritus.
    Type: Application
    Filed: December 6, 2005
    Publication date: May 22, 2008
    Inventors: Masatomo Kato, Tomoko Oda, Daisuke Shii
  • Publication number: 20060258703
    Abstract: It is intended to find out a novel pharmacological effect of a piperidine derivative (I). Because of having an excellent antipruritic effect, the piperidine derivative (1) is useful as a therapeutic agent for itching of any types such as eye itching, skin itching and systemic itching.
    Type: Application
    Filed: July 16, 2004
    Publication date: November 16, 2006
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Daisuke Shii, Tomoko Oda